US Patent

US9550780 — Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

Method of Use · Assigned to Auspex Pharmaceuticals Inc · Expires 2033-09-18 · 7y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects new pharmaceutical compositions and methods for treating chronic hyperkinetic movement disorders using benzoquinoline compounds that inhibit vesicular monoamine transporter 2 activity.

USPTO Abstract

The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3055 — Austedo
U-3055 — Austedo
U-3055 — Austedo
U-1995 — Austedo
U-1995 — Austedo
U-1995 — Austedo
U-1995 — Austedo
U-3055 — Austedo
U-1995 — Austedo
U-3055 — Austedo
U-3055 — Austedo

Patent Metadata

Patent number
US9550780
Jurisdiction
US
Classification
Method of Use
Expires
2033-09-18
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Auspex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.